Abstract
The aim of our study was to determine the incidence of Urinary Tract Infections (UTI) following intradetrusor onabotulinumtoxinA injections within our trust. This was a retrospective study of all patients who underwent intradetrusor onabotulinumtoxinA injections at our trust from August 2005 to 2015. Information was taken from our botulinum database, clinic letters and microbiology results. The primary outcome criterion was a positive urine culture together with symptoms suggestive of infection within 6 months post-procedure. A total of 290 intradetrusor onabotulinumtoxinA procedures were performed on 86 patients. The rate of UTI within 6 months following a procedure was 33%. There was a high resistance rate to our standard antibiotic prophylaxis, which was changed together with the addition of pre-procedure urine cultures and an on the day urine dipstick test. A re-audit was performed between January and June 2016 of 41 procedures and showed a reduction in UTI incidence to 20%. The rate of UTI post procedure within our trust was 33%. Following the implementation of multiple management protocol changes, a re-audit showed a reduction of UTI incidence to 20%.
Subject
Urology,Obstetrics and Gynecology
Reference14 articles.
1. Abrams P, Artibani W, Cardozo L, et al. International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28:287.
2. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NICE Guideline No. 123, 2019. Accessed 27/01/23. Available from: www.nice.org.uk/guidance/ng123
3. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-19.
4. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-9.
5. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin Botox®, intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275-287.